<DOC>
	<DOCNO>NCT02126761</DOCNO>
	<brief_summary>In study , safety immunogenicity current formulation aTIV compare aTIV-modified formulation dosage MF59 adjuvant double triple and/or dosage 3 influenza virus strain double , independently-living elderly subject ≥ 65 year age .</brief_summary>
	<brief_title>Safety Immunogenicity Different Formulations Adjuvanted , Trivalent Subunit Influenza Vaccine Elderly Subjects 65 Years Age Above</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Male female subject ≥65 year age day screen healthy chronic illness stable well control . 2 . Subjects assess mentally competent , give informed consent nature study explain accord local requirement 3 . In good health determine : 1 . Ability live independently 2 . Medical history 3 . Physical examination 4 . Clinical judgment Investigator 4 . Able understand comply study procedures visit , able complete eDiary 5 . Individuals access work telephone able receive periodic telephone call 1 . Individuals receive type influenza vaccine ( licensed experimental ) within past 6 month 2 . Individuals receive licensed vaccine within 30 day ( inactivated vaccine ) 42 day ( live vaccine ) prior enrollment study 3 . Individuals cancer except : 1 . Benign localize skin cancer 2 . Localized prostate cancer clinically stable ≥ 2 year without treatment 3 . Cancer remission ≥ 10 year ( end cancer treatment ) 4 . Individuals autoimmune disease ( include rheumatoid arthritis ) 5 . Individuals diabetes mellitus , type I 6 . Individuals body mass index ( BMI ) ≤18 ≥35 . 7 . Asthma great mild severity / exacerbations 2 day per week 8 . Congestive heart failure symptom severe severe dyspnea short walk climb single flight stair ( example , great New York Heart Association class 2 ) 9 . History progressive severe neurologic disorder include limited multiple sclerosis , Parkinson 's disease , GuillainBarré syndrome , amyotrophic lateral sclerosis , CreutzfeldtJakob disease , epilepsy disorder require medication control , encephalitis , Alzheimer 's CVA 10 . Individuals hypersensitive ovalbumin , chicken protein , chicken feather , influenza viral protein , kanamycin neomycin sulfate component vaccine study 11 . Individuals history neurological symptom sign , anaphylactic shock follow administration vaccine 12 . Individuals know suspect ( high risk develop ) impairment/alteration immune function result , example , . Receipt immunosuppressive therapy ( defined follow ) within past 60 day and/or anticipate receive immunosuppressive therapy point within 21 day Visit 1. . Cancer chemotherapy/radiotherapy ii . Systemic corticosteroid ( i.e. , 15 mg great per day prednisone equivalent ) iii . Chronic use inhaled/intranasal high potency corticosteroid ( budesonide 800 μg per day fluticasone 750 μg per day ) b . Receipt immunostimulants c. Receipt parenteral immunoglobulin preparation , blood product and/or plasma derivate within past 3 month full length study d. Suspected know HIV infection HIVrelated disease 13 . Individuals know suspected history drug alcohol abuse 14 . Individuals , within past 12 month , laboratory confirm influenza disease 15 . Individuals , within past 30 day receive investigational agent . 16 . Individuals plan receive another vaccine within 30 day receipt study vaccination . 17 . Individuals , within past 14 day , experience : 1 . Any acute disease include worsen underlying respiratory disease asthma COPD 2 . Infections require systemic antibiotic antiviral therapy ( chronic antibiotic therapy urinary tract prophylaxis acceptable ) 18 . Individuals take part another clinical study 19 . Individuals research staff directly involve clinical study family member household member research staff . Research staff include individual direct indirect contact study subject , study site personnel access study document contain subject information . This would include receptionist , person schedule appointment make screen call , regulatory specialist , laboratory technician , etc . 20 . Individuals behavioral cognitive impairment psychiatric condition , opinion investigator , may interfere subject 's ability participate study . 21 . Vulnerable subject , e.g . subject keep detention , soldier , employee sponsor clinical research organization involve study 22 . Individuals condition , opinion investigator , might interfere evaluation study objective .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Influenza</keyword>
	<keyword>elderly</keyword>
	<keyword>adjuvant</keyword>
</DOC>